牛牛AI助理已提取核心訊息
Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
製藥公司Conduit Pharmicals報告稱，截至2023年12月31日的年度淨虧損爲50萬美元，而上一年的淨虧損爲490萬美元。該公司用於經營活動的現金也有所增加，2023年爲770萬美元，高於2022年的230萬美元。儘管完成了總額爲2,000萬美元的合併和私募配售，但Conduit Pharmicals在年底的累計赤字爲1,130萬美元，並承認對其繼續經營的能力存在重大疑問。該公司的未來計劃包括通過股權或債務融資尋求額外資金，以支持其業務計劃。Conduit Pharmicals面臨行業風險，例如監管部門的批准以及對關鍵產品和客戶的依賴。該公司的財務報表是在假設將繼續作爲持續經營企業編制的，如果公司無法繼續運營，則不進行必要的調整。
製藥公司Conduit Pharmicals報告稱，截至2023年12月31日的年度淨虧損爲50萬美元，而上一年的淨虧損爲490萬美元。該公司用於經營活動的現金也有所增加，2023年爲770萬美元，高於2022年的230萬美元。儘管完成了總額爲2,000萬美元的合併和私募配售，但Conduit Pharmicals在年底的累計赤字爲1,130萬美元，並承認對其繼續經營的能力存在重大疑問。該公司的未來計劃包括通過股權或債務融資尋求額外資金，以支持其業務計劃。Conduit Pharmicals面臨行業風險，例如監管部門的批准以及對關鍵產品和客戶的依賴。該公司的財務報表是在假設將繼續作爲持續經營企業編制的，如果公司無法繼續運營，則不進行必要的調整。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了